Brought to you by 
Block Drug pays $50mm for Atrix periodontal disease products
28 Aug 2001
Executive Summary
Block Drug (Rx, dental & consumer products) will pay over $50mm for North American and certain European marketing rights to Atrix's (drug delivery) first three products for treatment of periodontal disease.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Block Drug pays $50mm for Atrix periodontal disease products
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice